736 / 1082
S720
ESTRO 36 2017
_______________________________________________________________________________________________
metastases reported a pain flare (grade I), 5 patients with
lymph node metastases reported diarrhea (grade I in three
patients, grade II in two patients).
Conclusion
SBRT might safely and effectively be used to postpone ADT
in patients with oligometastatic recurrence of prostate
cancer.
EP-1357 moderate hypofractionated-imrt of prostate
bed after radical prostatectom : acute toxicity
J. Valero Albarran
1
, A. Ruiz Herrero
2
, A. Montero
1
, E.
Sanchez
1
, E. Castro
3
, D. Olmos
3
, M. Hernandez
1
, R.
Ciervide
1
, X. Chen
1
, B. Alvarez
4
, M. Garcia Aranda
4
, M.
Lopez
1
, M. Serrano
5
, L. Osorio
6
, M. Asenjo
7
, P. Fernandez
Leton
8
, A. Acosta
1
, O. Hernando Requejo
1
, C. Rubio
1
1
Hospital University HM Sanchinarro, Radiation Oncology,
Madrid, Spain
2
Infanta Cristina Hospital, Radiiation Oncology, Madrid,
Spain
3
Hospital University HM Sanchinarro, Medical Oncology,
Madrid, Spain
4
Hospital University HM Sanchinarro Radiation Oncology
Madrid, Radiation Oncology, Madrid, Spain
5
Hospital University HM Sanchinarro, Urology, Madrid,
Spain
6
Hospital University HM Sanchinarro Radiation Oncology
Madrid, Urology, Madrid, Spain
7
Hospital University HM Sanchinarro, Radiophisyc,
Madrid, Spain
8
Hospital University HM Sanchinarro, Radiophisic,
Madrid, Spain
Purpose or Objective
Hypofractionated radiation therapy as primary treatment
for prostate cancer is currently being investigated in large
phase 3 trials. However, evidences in post-operative
setting are scarce. We report our experience about
feasibility and acute toxicity of a moderate
hypofractionated intensity modulated radiotherapy
(Hypo-IMRT) schedule for prostate cancer (PC) after
radical prostatectomy.
Material and Methods
From October 2015 to July 2016, 23 patients (pts) were
included for adjuvant (60,9%) or salvage radiation therapy
(39,1%). They were classified with
NCCN
criteria in: low (2
pts), intermediate (13 pts) and high risk (8 pts). Median
age was 63 years (range 55-77 years). Median PSA
pretreatment was 0.31ng/mL (range 0.04 – 4.38ng/mL).
Pathological characteristics are summarized in Table 1.
Two internal gold-fiducial markers were placed
transperineally guided by transrectal ultrasound, in every
patient before treatment. CTV was countered according
to RTOG guidelines and expanded 3 mm posteriorly and 5
mm in all other direction to create the PTV. All patients
underwent treatment with IMRT up to a total dose of
62.5Gy in 25fx (2,5Gy/day) in a Novalis linac. Daily
verification was performed with IGRT-Exactrac®, and 6D-
robotic couch. Six (26%) patients received androgen
deprivation. Acute toxicity was assessed according to
RTOG/EORTC criteria and was recorded weekly during
treatment and one month after radiation therapy.
Gleason score:
6 7(3+4) 7(4+3) 8-10 9% 35% 26% 30%
Seminal vesicles invasion:
-Yes -No 17% 83%
Extracapsular extension:
-Yes -No 61% 39%
Positive
Margin
: -Yes -No 48% 52%
Perineural invasion:
-Yes -